Michael Lilly, MD
Medical University of South Carolina
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Lilly, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04207255 · Addition of Opaganib to Androgen Antagonists in Patients With mCRPCMedical University of South Carolina · completed · Prostate Cancer · principal investigator
- Ph1/Ph2NCT03712371 · Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer PatientsMedical University of South Carolina · terminated · Prostate Cancer · principal investigator
- N/ANCT03677076 · Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate CancerMedical University of South Carolina · completed · Prostate Cancer · principal investigator
- Ph1NCT03465345 · Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer PatientsMedical University of South Carolina · withdrawn · Prostate Cancer · principal investigator
- Ph2NCT03149159 · Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabMedical University of South Carolina · withdrawn · Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma · principal investigator
- Ph1NCT03092635 · AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine TherapyMedical University of South Carolina · terminated · Breast Cancer · principal investigator
- Ph2NCT02946996 · Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation TherapyMedical University of South Carolina · terminated · Prostate Cancer · principal investigator
- Ph2NCT02772562 · Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical ProstatectomyMedical University of South Carolina · terminated · Prostatic Neoplasms · principal investigator
- Ph1NCT01949519 · Docetaxel and Lycopene in Metastatic Prostate CancerMedical University of South Carolina · completed · Adenocarcinoma of the Prostate · principal investigator
- Ph1NCT01820299 · Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced CancerMedical University of South Carolina · completed · Solid Cancers · principal investigator
- Ph1/Ph2NCT01335204 · Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate CancerMedical University of South Carolina · terminated · Prostate Cancer, Prostatic Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 3: Targeting SK2/S1P Signaling for the Regulation of c-Myc and Tumor SuppressionP01CA203628 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Carolyn D Britten · fiscal years 2016 to 2021Named on NCT04207255
- Phase 1 Bioassay-guided Trial of Lycopene and Docetaxel for Prostate CancerR21CA166839 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MICHAEL B LILLY, Xiaolin Zi · fiscal years 2013 to 2014Named on NCT01949519
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.